LifeArc Ventures’ portfolio company RQ Biotechnology has announced that the first of its discovered monoclonal antibodies to…
LifeArc’s Chief Scientific Officer Dr Dave Powell comments on news that lecanemab has received regulatory and safety approval from the FDA.
Dave Powell on why LifeArc is evolving the way we do our science – and the difference we hope it will make to people’s lives.
We’ve seen some exciting scientific progress, forged new partnerships and launched some new landmark initiatives.
Three-year partnership to improve healthcare for thousands of people across Europe living with bronchiectasis.
We cautiously welcome the Government's announcement on how their £50m commitment into MND research will be spent.
Results of an international repurposing study show favipiravir could help with COVID-19.
Welcome to Anna Tomlinson, who joins LifeArc as our first Chief Communications Officer.
First major funding call announced as part of our £100m Chronic Respiratory Infection Translational Challenge